双去水半乳糖醇治疗晚期非鳞状宫颈癌的II期评估。一项妇科肿瘤学组研究。
Phase II evaluation of dianhydrogalactitol in the treatment of advanced non-squamous cervical carcinoma. A Gynecologic Oncology Group study.
作者信息
Stehman F B, Blessing J A, Homesley H D, Currie J L, Yordan E L
出版信息
Invest New Drugs. 1984;2(3):331-3. doi: 10.1007/BF00175387.
PMID:6511240
Abstract
In an on-going Phase II evaluation, dianhydrogalactitol (NSC 132313) was administered intravenously to 28 patients with advanced or recurrent non-squamous cell carcinoma of the cervix. The initial dosage was 60 mg/m2/wk with escalation to 75 mg/m2/wk if there were no adverse effects. Twenty-seven patients were evaluable for toxicity and response. There was one complete response and one partial response. Adverse effects were not infrequent but tolerable.
摘要
在一项正在进行的II期评估中，对28例晚期或复发性宫颈非鳞状细胞癌患者静脉注射了双去水半乳糖醇（NSC 132313）。初始剂量为60mg/m²/周，如果没有不良反应则增至75mg/m²/周。27例患者可评估毒性和反应。有1例完全缓解和1例部分缓解。不良反应并不罕见，但可以耐受。
相似文献
1
Phase II evaluation of dianhydrogalactitol in the treatment of advanced non-squamous cervical carcinoma. A Gynecologic Oncology Group study.双去水半乳糖醇治疗晚期非鳞状宫颈癌的II期评估。一项妇科肿瘤学组研究。
Invest New Drugs. 1984;2(3):331-3. doi: 10.1007/BF00175387.
2
Phase II trial of galactitol 1,2:5,6-dianhydro (NSC 132313) in the treatment of advanced gynecologic malignancies: a Gynecologic Oncology Group study.
Gynecol Oncol. 1983 Jun;15(3):381-90. doi: 10.1016/0090-8258(83)90056-2.
3
Dianhydrogalactitol and cisplatin in combination for advanced cancer of the uterine cervix.二去水半乳糖醇与顺铂联合治疗晚期宫颈癌
Cancer Treat Rep. 1982 Oct;66(10):1809-12.
4
Phase II evaluation of dianhydrogalactitol in lung cancer: a Southwest Oncology Group Study.双去水半乳糖醇治疗肺癌的II期评估：西南肿瘤协作组研究
Cancer Treat Rep. 1981 Jan-Feb;65(1-2):115-7.
5
Phase II evaluation of dianhydrogalactitol in advanced head and neck carcinomas.去水卫矛醇在晚期头颈癌中的II期评估。
Cancer Treat Rep. 1979 Nov-Dec;63(11-12):2081-3.
6
Phase II evaluation of galactitol in head and neck cancer: a Southwest Oncology Group Study.半乳糖醇用于头颈癌的II期评估：一项西南肿瘤协作组研究
Med Pediatr Oncol. 1983;11(4):281-3. doi: 10.1002/mpo.2950110414.
7
Phase II evaluation of dianhydrogalactitol in the treatment of advanced endometrial adenocarcinoma: a Gynecologic Oncology Group Study.
Cancer Treat Rep. 1983 Jul-Aug;67(7-8):737-8.
8
Phase II trial of dianhydrogalactitol in advanced soft tissue and bony sarcomas: a Southwest Oncology Group study.去水卫矛醇治疗晚期软组织和骨肉瘤的II期试验：一项西南肿瘤协作组的研究
Cancer Treat Rep. 1979 Apr;63(4):553-5.
9
Dianhydrogalactitol (NSC-132313): phase II study in solid tumors.双脱水半乳糖醇（NSC - 132313）：实体瘤的II期研究。
Eur J Cancer (1965). 1979 Jul;15(7):971-4. doi: 10.1016/0014-2964(79)90280-9.
10
Phase II trial of dianhydrogalactitol in advanced renal cell carcinoma: a Southwest Oncology Group study.去水卫矛醇治疗晚期肾细胞癌的II期试验：一项西南肿瘤协作组研究
Cancer Treat Rep. 1982 May;66(5):1231-2.
引用本文的文献
1
Chemotherapy for advanced or recurrent carcinoma of the cervix.晚期或复发性宫颈癌的化疗
Curr Oncol Rep. 2001 Jan;3(1):33-40. doi: 10.1007/s11912-001-0040-5.
本文引用的文献
1
Phase II evaluation of dianhydrogalactitol in the treatment of advanced endometrial adenocarcinoma: a Gynecologic Oncology Group Study.
Cancer Treat Rep. 1983 Jul-Aug;67(7-8):737-8.
2
Phase II trial of galactitol 1,2:5,6-dianhydro (NSC 132313) in the treatment of advanced gynecologic malignancies: a Gynecologic Oncology Group study.
Gynecol Oncol. 1983 Jun;15(3):381-90. doi: 10.1016/0090-8258(83)90056-2.
Zotero 插件